# Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-to-participate-in-the-stifel-2025-healthcare-conference-629bd038
Ticker: SENS
Company: Senseonics
Source: Senseonics
Published: 2025-11-10 13:05 EST
## Summary

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the...

## Article Body
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY.

2025 Stifel Healthcare Conference Format: Fireside chat and one-on-one meetings Date: Wednesday, November 12, 2025 Time: 4:40 pm ET Webcast: Click here

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com .

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact Jeremy Feffer LifeSci Advisors investors@senseonics.com
## Recent Company News
- 2026-06-10 12:00 EST — [Senseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365](https://biopharmsignal.com/news/SENS/senseonics-and-welldoc-partner-to-develop-next-generation-app-for-eversense-365-6acf0328) — Source: Senseonics
- 2026-06-06 21:00 EST — [Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems](https://biopharmsignal.com/news/SENS/real-world-evidence-of-eversense-365-presented-at-ada-demonstrating-strong-perfo-37d528e7) — Source: Senseonics
- 2026-06-01 12:00 EST — [Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026](https://biopharmsignal.com/news/SENS/senseonics-highlights-analyst-event-and-oral-presentation-of-eversense-365-real--5826a5ba) — Source: Senseonics
- 2026-05-07 20:01 EST — [Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-reports-first-quarter-2026-financial-results-a7b4bee3) — Source: Senseonics
- 2026-05-04 20:01 EST — [Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/SENS/senseonics-announces-closing-of-92-million-public-offering-and-full-exercise-of--0e1d5fdd) — Source: Senseonics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)